Flunazol 150 mg (Capsule)

Unit Price: ৳ 20.00 (12's pack: ৳ 240.00)

Medicine Details

Category	Details
Generic	Fluconazole
Company	Pharmadesh laboratories ltd
Also available as	Flunazol 50 mg capsule Flunazol 50 mg suspension

Vaginal Candidiasis
Oropharyngeal Candidiasis
Oesophageal Candidiasis
Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
Kerion
Pityriasis versicolor
Onychomycosis
Invasive candidal infections and cryptococcal infections (including meningitis)
Prevention of cryptococcal meningitis
Prevention of fungal infections in immunocompromised patients
Systemic Candidiasis and Cryptococcal infection
Superficial Candidiasis
Fungal urinary tract infections
Disseminated candidiasis
Prophylaxis for fungal infection in neutropenic cancer patients
Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis

Triazole antifungal agent, potent inhibitor of fungal cytochrome P-450 dependent enzymes responsible for ergosterol synthesis

Adults:
- Vaginal Candidiasis: 150 mg as a single dose
- Oropharyngeal Candidiasis: 200 mg in 1st day followed by 100 mg daily for 14 days
- Oesophageal Candidiasis: 200 mg in 1st day followed by 100 mg daily for 14-30 days
- Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea: 150 mg weekly for 4-6 weeks
- Kerion: 50 mg daily for 20 days
- Pityriasis versicolor: 400 mg as a single dose
- Onychomycosis: 150 mg weekly for 12 months
- Invasive candidal infections and cryptococcal infections (including meningitis): Orally or by IV infusion, 400 mg on first day then 200-400 mg daily
- Prevention of cryptococcal meningitis: Orally or by IV infusion 200 mg daily
- Prevention of fungal infections in immunocompromised patients: Orally or by IV infusion, 50-400 mg daily
Children over 1 year:
- In Superficial Candidiasis: 1-2 mg/kg daily
- In Systemic Candidiasis & Cryptococcal infection: 3-6 mg/kg daily
Specific Population:
- Elderly patient: The normal dose should be used if there is no evidence of renal impairment
- Renal Impairment: No adjustment in single dose therapy is required. In multiple dose therapy of patients with renal impairment, normal doses should be given on days 1 and 2 of treatment and thereafter the dosage intervals should be modified based on creatinine clearance

Potential interaction with coumarin type anticoagulants
Potential interaction with oral sulphonyl ureas
Potential interaction with hydrochlorothiazide
Potential interaction with phenytoin
Potential interaction with rifampicin
Potential interaction with combined oral contraceptive
Potential interaction with cyclosporin
Absence of clinically significant impairment during co-administration with food, cemetidine, antacids, or following total body irradiation for bone marrow transplantation
Potential interaction with theophylline

Hypersensitivity to Fluconazole or related triazole compounds

Common: gastrointestinal symptoms (nausea, abdominal discomfort, diarrhea, flatulence)
Rare: rash (incidence less than 1%)
Rare: anaphylaxis

Avoid use in pregnancy or in women of childbearing potential unless adequate contraception is employed

Monitoring of hepatic, renal, hematological, and biochemical function tests in patients with serious underlying diseases
Assessment of risk-benefit ratio with significant rise of liver enzymes
Rare occurrence of exfoliative cutaneous reactions
Caution in patients with rash during treatment
Avoid use during lactation
Unlikely impairment of driving or machinery use

Supportive and symptomatic treatment, with potential for gastric lavage and forced volume diuresis